Imugene: Secures approval for PD1-Vaxx trial
- Imugene has received a second Human Research Ethics Committee approval to begin a phase one trial of PD1-Vaxx in Australia
- The Macquarie University hospital in Sydney will be joining the Chris O’Brien Lifehouse as the second hospital to receive ethics approval
- Then the aim of this phase one trial is to determine the safety, efficacy, tolerability and optimal dose of PD1-Vaxx
- PD1-Vaxx used to treat tumours such as lung cancer by obstructing programmed death-ligand one (PD-1/PD-L1) and producing an anti-cancer effect
- PD-1/PD-L1 is a type of protein that plays a role in suppressing the adaptive arm of the immune system
- Imugene up a steady 8.33 per cent on the market and shares are trading for 3.9 cents each
